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ABSTRACT 
Glioblastoma multiforme (GBM) is the most aggressive primary brain cancer in 
adults and unfortunately, characterized by a poor prognosis. Standard treatments like 
surgical resection and chemotherapy are marginally effective. Despite aggressive therapy, 
the disease ultimately recurs. Local control-released chemotherapy may be administered 
via carmustine (BCNU) polymer-loaded biodegradable wafers (Gliadel
® wafers) to the 
cavity upon surgical resection. One significant limitation of this modality is the instability 
of BCNU in aqueous media. Moreover, the effective therapeutic distance of the wafers 
extends only a few millimeters from the resection cavity, while recurrences occur often 
centimeters away. New carriers and pharmacological agents are being actively explored. 
One such carrier is derived from a novel set of poly(DL-lactide-co-glycolide-b–ethylene 
glycol-b-DL-lactide-co-glycolide) (PLGA-PEG-PLGA) thermo-gelling tri-block 
copolymers capable of sustained release of paclitaxel. Paclitaxel has been shown in vitro 
and in vivo to be effective against glioma cells while having a much slower degradation 
rate than carmustine; this slower degradation may allow deeper penetration into the brain 
than BCNU and an effective concentration that can be sustained for a longer period. We 
seek to test whether thermo-gelling hydrogel carriers of paclitaxel could result in novel 
therapies for the treatment of GBM. We also seek to optimize the configuration of the 
thermo-gelling hydrogels within the resection cavity to maximize drug delivery to the 
surrounding brain. 
Keywords: Paclitaxel, Glioblastoma multiforme, controlled-release, thermo-gelling 
polymers 
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INTRODUCTION: 
  Approximately each year in the United States there are 22,500 new diagnoses of 
malignant primary brain cancers. [1] Gliomas, the most common form of primary brain 
cancers in adults, account for nearly 51% of all central nervous system (CNS) tumors. [2] 
The most aggressive form of glioma and primary brain cancer is glioblastoma multiforme 
(GBM), which has a worldwide annual incidence of 74,000 cases and a median overall 
survival (OS) of approximately 9 months. [2-5] Treatments for primary malignant 
gliomas range from surgical resection [6, 7] to external beam radiation and 
chemotherapy. [8, 9] 
  A common practice in cancer treatment is the use of systemic therapy. These 
therapies have many inherent drawbacks, such as harmful side effects (e.g. vomiting, 
hair-loss, and uncontrolled weight loss). However, the biggest drawback of systemic 
therapy is decreased concentrations of drug reaching the target area due to dilution effects 
as the drug passes through the body. Another important limitation in systemic cancer 
treatment for brain malignancies is the blood-brain barrier (BBB). The BBB is a highly 
impermeable barrier due to tight-junction formation of endothelial cells. The BBB 
formed by cerebral endothelial cells is unique in the degree of “tightness” achieved, 
which inhibits efficient drug transport from the circulating blood to the cerebrospinal 
fluid (CFS). [10-12] Most systemically administered therapies do not adequately 
penetrate to the brain tumor tissue as a result of this biological barrier. Therefore, 
employing localized therapies that are directly placed within the resection cavity allow 
for a far greater drug selection and potential effectiveness.   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Figure 1: A) Implantation of Gliadel
® wafers into a resection cavity. [13] B) Mechanism of drug metabolism and 
elimination from the brain. [14] 
________________________________________________________________________ 
Upon surgical resection, local chemotherapy may be administered to the resection 
cavity via the use of carmustine (BCNU, 1,3-bis[2-chloroethyl]-1-nitrosourea) loaded 
wafers (Gliadel
® wafers by MGI Pharma). The wafers are 14 mm x 1 mm biodegradable 
p(CCP:SA) (20:80 poly[bis] (p-carboxyphenoxy) propane/sebacic acid) discs loaded with 
3.85% (7.7 mg) BCNU, where drug is released through a controlled release mechanism 
from the biodegradable matrix. [15] After surgical resection up to 8 wafers are implanted 
into the resection cavity where they will be subsequently subjected to natural brain fluids, 
which penetrate and degrade the porous matrix, allowing BCNU to diffuse into the 
surrounding brain parenchyma. (Figure 1) 
However, one significant limitation of this modality is the instability of BCNU in  
aqueous media; the half-life (t1/2) of BCNU is approximately 110 minutes. [16] In 
addition to the drug’s instability, carmustine has high capillary permeability thus causing 
rapid elimination from the brain tissue, and thus affecting the efficacy of the treatment. 
[16] The largest problem, augmented by the limitations of BCNU, is GBM recurrences 
appear in an area up to two centimeters from the initial excision cavity, while penetration  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of the drug is limited to a few millimeters from the polymer-tissue interface. [16-18] Due 
to these inherent limitations alternative approaches for localized chemotherapy are 
needed that result in sustained and effective drug concentrations at farther distances from 
the resection cavity.  
  One such modality that is being actively explored is the use of polymeric carriers 
for the controlled delivery of paclitaxel. The polymeric carrier method allows for 
prolonged, sustained continuous and predictable local release of drug, while 
simultaneously limiting systemic exposure. [15] As described in Fung and Saltzman [19], 
the classes of polymers, range from proteins to polyacrylates and silicone elastomers and 
are characterized by whether they are permanent implants or biodegradable ones, and by 
their biocompatibility.  
Paclitaxel, an anti-microtubule, anti-neoplastic agent isolated in 1963 from the 
pacific yew Taxus brevifolia, functions by promoting assembly and stabilization of 
microtubules, thereby inhibiting cell proliferation. [20, 21] It has been shown that the 
degradation rate is much slower than that of carmustine and effective in both in vitro and 
in vivo against glioma cells. [12, 21-23] However, the half-life depends upon the duration 
of infusions. [20] In addition, the hydrophobic nature reduces the capillary permeation in 
brain tissue. [16]  
  A promising new type of polymeric carrier for the treatment of GBM is a novel 
set of thermo-gelling block-copolymers, poly(DL-lactide-co-glycolide-b–ethylene glycol-
b-DL-lactide-co-glycolide) (PLGA-PEG-PLGA) capable of conforming to the shape of 
the resection cavity and providing the same or better sustained release of paclitaxel, than 
it’s predecessor, PEG-PLGA-PEG tri-block co-polymers. [24-28] When these polymers  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are below the critical gelation temperature (CGT), they can be easily loaded with 
hydrophobic drugs in solution and above the CGT, the polymers form drug-releasing 
hydrogels. Below the CGT, micelle formation works as a surfactant, increasing the 
solubility of hydrophobic drugs maximally 2000-fold in aqueous solutions of these 
polymers. [29] 
  Many agents that show great promise in vitro and in animal models often have 
little to no impact on the disease clinically. Animal models are necessary, but have 
significant disadvantages when attempting to correlate those findings with the human 
response. In particular, the size of the rat brain is small enough to allow efficient 
diffusive delivery and therefore, results that are often found in rat models cannot be 
correlated with the human response. One way to predict the effectiveness of a drug 
delivery system is to use computational modeling based on the characterization of the 
drug transport properties. However, experimental determination of the polymer must be 
carried out to obtain the necessary parameters for the modeling systems.  
  We seek to show that thermo-gelling polymeric carriers of paclitaxel can be a 
novel and effective therapy in the treatment of GBM on the basis that drug diffusion is 
occurring at a sufficient rate to provide therapeutic concentrations to the resection cavity 
before degradation of the hydrogel occurs. Analogs, in the form of dyes or molecular 
markers are used to mimic the properties of paclitaxel and carmustine. Solubility and 
diffusivity of the analogs need to be characterized and optimized. This work should 
further the process of developing alternative paclitaxel loaded hydrogel treatment 
strategies for the treatment of primary and relapsed/refractory GBM.   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Figure 2: Chemical Structures of drugs and analogs. A) Carmustine B) Paclitaxel C) Congo Red D) Sudan Black B 
E) Piroxicam and F) Fluorescein.  
________________________________________________________________________ 
MATERIALS AND METHODS 
CREATING STOCK DYE SOLUTIONS AND CALIBRATION CURVES 
  Stock solutions of each dye were made by dissolving in DPBS to create 108 µM 
solution of fluorescein (Sigma, C20H12O5; Mw = 332.32, Emax = 490 nm in 0.1 M Tris at 
pH 8.0); 517 µM solution of Congo Red (Sigma, C32H22N6Na2O6S2; Mw = 696.68; 40% 
dye content; Emax = ~500 nm; solubility: 0.03g/mL of H2O); and 679 µM Sudan Black B 
(Sigma, C29H24N6; Mw = 456.54; Emax = 598 – 605 nm; solubility: 0.1 mg/mL in H2O). 
Due to the hydrophobic nature of Sudan Black B, 0.5% by volume of Tween 20 (1.25 
mL) was added to the DPBS buffer solution. The addition of Tween 20 ensures a 
smoother calibration curve and the ability to obtain more data. The effect of Tween 20 on 
the solubility of Sudan Black B in solution is negligible. (Figure 2)  
  8 
The concentration of the primary stock solution for each dye was calculated and 
subsequently diluted by a factor of 2 to obtain the concentrations to be used as the 
standards. The samples were then run on a spectrophotometer (BIO-RAD SmartSpec 
3000
TM) for Fluorescein and Congo Red, and a 96-well plate spectrophotometer 
(Molecular Devices SoftMax
® Pro Version 4.3 Software) for Sudan Black B
 and 
Piroxicam (Sigma, C15H13N3O4S; Mw = 331.37; Emax = 276 nm) to obtain the absorbance 
of each standard at Emax.  
  Dyes are also loaded into the hydrogels to create a calibration curve of dye in the 
hydrogel. From our library of polymers (Appendix A) AT-19 [PLGA-PEG-PLGA; 1,000-
1,000-1,000 (3:1, DL-lactide/glycolide)] was chosen for Fluorescein and Congo Red and 
AT-21 [PLGA-PEG-PLGA; 1,142-1,000-1,142 (2.7:1, DL-lactide/glycolide)] was chosen 
for Congo Red, Sudan Black B and Piroxicam. Dye was loaded into the AT-19 matrix 
along with DPBS using the Equation (1):  
               (1) 
where α is the grams of AT-19 and δ is the grams of DPBS + dye. Since AT-19 is soluble 
up to a 37 weight % (Figure 3a), solutions of AT-19 were created at 23 weight %. 
Equation (2) was then used to convert δ from Equation (1) to µL to determine the amount 
of DPBS + dye solution needed to create the 23 weight % hydrogel: 
               (2)     
where x is the µL of DPBS + dye, δ is the grams of DPBS + dye and 1.1 is the density of 
the polymer. To obtain the concentration of dye that would actually be in the hydrogel 
solution the standard dilution equation was used: 
                 (3)   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A             B   
Figure 3: Thermo-gelling hydrogel matrix of poly(ethylene glycol-co-L-lactide-co-glycolide) as novel drug 
delivery system. A) Phase diagram of thermo-gelling polymer PLGA-PEG-PLGA; 1,000-1,000-1,000 (3:1, DL-
lactide/glycolide) at different concentrations in aqueous solution. B) Phase diagram of thermo-gelling polymer PLGA-
PEG-PLGA; 1,142-1,000-1,142 (2.7:1, DL-lactide/glycolide) at different concentrations in aqueous solution. Maximum 
solubility of PLGA-PEG-PLGA; 1,000-1,000-1,000 (3:1, DL-lactide/glycolide) is 37% and maximum solubility of 
PLGA-PEG-PLGA; 1,142-1,000-1,142 (2.7:1, DL-lactide/glycolide) is 17%. 
________________________________________________________________________ 
where V1 is the volume of DPBS + dye in mL, C1 is the concentration of the DPBS + dye 
that will be need to be added to the polymer, V2 is the volume of polymer and C2 is the 
standard concentration to be chosen from the calibration curve of dye in buffer. 
Combining Equations (1), (2), and (3) C1 can be determined by the following equation:  
                                                                            (4) 
where γ is the chosen concentration from the dye in buffer calibration curve.  
Despite the polymers being synthesized following the same protocol, the physical 
properties of the polymers in the library differ slightly. AT-21 is soluble only up to 17 
weight % (Figure 3b), therefore, the 0.23 term in Equation 1 was substituted with 0.17. 
Upon loading the dye solution in the polymer matrix, the solution was placed in a 
spinning rack at 4°C overnight for AT-19 and two days for AT-21 to allow 
homogenization of dye and buffer.   
ENSURING HOMOGENOUS SOLUTION OF DYE IN HYDROGEL  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  After the allotted time mentioned above was reached, a 100µL sample was taken 
out in triplicate and measured in the respective spectrophotometer. If the absorbance 
readings were no greater than double, then it was assumed that the solution was 
homogenous.  
BRAIN PHANTOMS 
  The brain phantoms were adapted from The Brain Phantom Project [30]: 
however, the phantoms only contained 0.6% agarose and de-ionized H2O (dH2O) 
obtained from the NanoPure water filtration system. Deviations from the original 
protocol were necessary because Tris, 0.5M EDTA and Boric Acid, all of which are used 
in the original protocol, affect the formation of the hydrogel placed within the resection 
cavity. To create a 0.6% agarose brain phantom: 7.8 grams of agarose is dissolved in 
1300 mL of dH2O by placing the solution in the autoclave on a “liquid cycle” (15-minute 
sterilization). The solution is allowed to cool for 30-45 minutes before pouring into the 
casting mold. To create the resection cavity with a constant volume, a fully inflated 
endotracheal (ET) tube is placed into the agarose and secured in place. The casting mold 
with ET tube is then placed in 4°C overnight. (Figure 4) A 0.6% agarose concentration 
strikingly resembles the human brain when considering certain critical physical 
characteristics such as the human brain’s macroscopic characteristics (e.g. porosity, 
penetration values, drag forces). [31] 
DYE RELEASE PROFILES 
From hydrogel into buffer: In order to optimize and correlate the paclitaxel release profile 
within the brain with the dye analogs, diffusion coefficients must be determined. To   
  11 
A            B     
Figure 4: Agarose Brain Phantom Model. A) Experimental set-up: Styrofoam holding inflated ET tube vertically to 
create the resection cavity within the 0.6% agarose brain phantom model. B) 0.6% agarose brain phantom model 
________________________________________________________________________ 
achieve this goal, a constant concentration boundary condition was established. 
Piroxicam is dissolved into AT-21 polymer solutions at 2 mg/mL. After allowing 
homogenization, 600 µL of the polymer solution is loaded in duplicate into wells of a 
UV-transparent 24-well plate (BD Falcon
TM), which is placed at room temperature until 
the solution became a hydrogel. Two mL of DPBS + 0.5% Tween 20 is then pipetted 
over each gel and covered with a polyester adhesive film (VWR) to minimize 
evaporation. The entire set-up is then wrapped in parafilm and aluminum foil, which 
minimizes light exposure and placed at 37°C in a humid incubator with gentile agitation. 
At predetermined time-points, 100 µL samples of the supernatant are extracted and the 
absorbance read at Emax = 276 nm. Two mL of fresh DPBS + 0.5% Tween 20 is 
subsequently added. The data is then plotted and fitted to the equation: 
                                                                              (5) 
The cumulative mass % is plotted over the square root of time ( ), to obtain a linear plot 
where the slope,   is used to solve for the diffusion coefficient, D. [32]  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From hydrogel into brain phantom: After brain phantoms were prepared as outlined 
above, the resection cavity was filled 30% (8.3 mL) with hydrogel and allowed to sit at 
room temperature. To minimize “sweating” of the agarose, the phantoms were covered 
with clear plastic wrap. Because of the photosensitivity of Piroxicam, the brain phantoms 
were also kept in the dark for the duration of the experiment. At predetermined time-
points (t =0, 3 and 7 days post injection) the absorption of the dye from the hydrogel was 
measured and plotted to determine the release profile.  
COMPUTATIONAL MODELING   
  The transport model consisted of fluid, mass and drug transport created by Dr. 
Alexis Torres in our lab. Fluid transport in the brain is assumed to behave as a 
homogeneous porous media where the fluid has achieved steady state. It is also assumed 
that the surgery resulted in gross-total resection of the tumor and only scattered malignant 
cells remain in proximity to the cavity. Dimensions were taken from a magnetic 
resonance image (MRI) of a patient and used to construct an anatomically correct model. 
A two-dimensional model was used to reduce the computational time. A very important 
distinction that was not considered in the model was the difference between grey and 
white matter.  
The transport of fluid was assumed to have the same rheological properties as 
water at 37°C and can be described by combining the equation for mass conservation and 
the momentum equation for fluid flow. [32-34] Fluid removal via the lymphatic system 
(Fl) is assumed to be negligible due to the lack of a well-defined lymphatic system in the 
brain.   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Onset of edema after surgical resection is characterized by an increase in fluid in 
the extracellular space (ECS), resulting in an increase in hydraulic conductivity of the 
blood capillaries and serum leakage from the cerebral blood vessels. The variation of 
hydraulic conductivity with time in this model was taken from previous reports. [32, 33] 
It was also assumed that the surrounding hydraulic conductivity (within 3 mm) is 
uniformly affected by edema. The current model uses the following equation [32]: 
                               (6)  
where t is time in seconds and a and b are 9×10
-5 and 1.94×10
-5 s
-1 respectively. As a 
result of employing this equation, tumor hydraulic conductivity increases ten-fold from 
normal tissue and is 94% resolved at t = 3 days. 
  The tissue immediately surrounding the polymer implant consists of three distinct 
phases: interstitial/extracellular space (ECS), intracellular space (ICS), and the cellular 
membrane (M); and drug is always present in either a free or bound form. Free drug is 
present throughout all three phases, and the molar concentration of drug per total tissue 
volume, C, is expressed as [14, 16, 32]: 
                                (7) 
where C is the average free drug concentration, CECS, CICS, and CM are the free drug 
concentrations in the extracellular, intracellular, and cellular membrane spaces 
respectively, α and β are the volume fractions of the extracellular and cellular spaces 
respectively. The following partial differential equation describes the local concentration 
of drug molecules in brain tissue, assuming isotropism [14, 16, 32]:  
                    (8)  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where t is the time after implantation, DECS is the diffusion coefficient of the drug in the 
ECS, V is the fluid velocity field vector (derived by solving Darcy’s equation), and kbbb 
and ke are first-order elimination constants of capillary permeation and enzymatic/non-
enzymatic elimination respectively. To simplify, the following assumptions can be made: 
the drug is not bound or eliminated in the membrane phase, the concentration of bound 
drug is directly proportional to the concentration of free drug in the ECS and ICS (i.e., 
KECS = BECS/CECS and KICS = BICS/CICS), drug is eliminated by a first-order process and 
free drug is present in all three phases and in local equilibrium. Based on these 
assumptions, Equation (7) and (8) can be combined to give the general expression in 
terms of CECS [32]: 
                                      (9) 
where α
* is a constant that accounts for the effects in solute transport by local binding and 
cell membrane partitioning. [32] 
In the cavity, 100% of the drug is available for transport in the interstitial phase, 
and binding and partitioning is assumed to be negligible, and diffusion and convection 
take place freely. As a result, drug transport in the interstitial medium is expressed 
dependent of time by solving Darcy’s equation of fluid flow as illustrated [32]: 
                                      (10) 
where kc is the first-order degradation constant in the cavity. It was assumed that flow 
reaches equilibrium faster than drug diffusion. COMSOL Multiphysics 3.5a was used to 
simulate the fluid, mass, and drug transport. 
RESULTS  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Figure 5: Calibration Curve of Congo Red. A) Congo Red in DPBS buffer solution, B) Congo Red in PLGA-PEG-
PLGA; 1,000-1,000-1,000 (3:1, DL-lactide/glycolide), C) Congo Red in PLGA-PEG-PLGA; 1,142-1,000-1,142 (2.7:1, 
DL-lactide/glycolide). All readings were done at Emax = 479 nm 
________________________________________________________________________ 
CALIBRATION CURVES 
  Maximum concentrations were obtained by choosing the highest value still within 
the linear region of the calibration curve. This value indicates the maximum 
concentration that can be read accurately by the spectrophotometer. A maximum 
concentration of 39 µM was found for Fluorescein at an Emax = 490 nm in DPBS. (Data 
not shown) The maximum concentration of Congo Red was found to be 120 µM, at an 
Emax = 479 nm in DPBS. (Figure 5A) 
The maximum concentration of Sudan Black B was found to be 679 µM at an 
Emax = 575 nm in DPBS + 0.5% Tween 20. (Figure 6A) This concentration was not the 
maximum concentration in the linear region; however, this concentration was chosen 
because a saturated solution was achieved 679 µM, above this concentration Sudan Black 
B would no longer dissolve in solution. A maximum concentration of 1.8 mM was 
previously found for Piroxicam at an Emax = 276 nm. (Figure 7A)   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Figure 6: Calibration curve of Sudan Black B: A) Sudan Black B DPBS solution plus 0.5% by volume Tween 20 B) 
Sudan Black B in PLGA-PEG-PLGA; 1,142-1,000-1,142 (2.7:1, DL-lactide/glycolide). All readings were done at Emax 
= 595 nm. 
________________________________________________________________________ 
The calibration curve of Fluorescein loaded in AT-19 was unable to be 
determined due to the polymer inducing a quenching effect on the dye, therefore the 
measured absorbance was lower than what would be expected for the specific standard 
and, as a result, could not be correlated back to the standard concentration. (Data not 
shown). There were no quenching effects seen for Congo Red in AT-19 or AT-21, Sudan 
Black B or Piroxicam. (Figures 5B and 5C, 6B and 7B respectively) 
RELEASE PROFILES 
  Congo Red and Sudan Black B were continuously released from AT-21 while 
immersed in DPBS + 0.5% by volume Tween 20. The release of Congo Red was done 
both at room temperature and at physiological temperature (37°C). (Appendix B) Since 
Sudan Black B is extremely hydrophobic, the release was only done at physiological 
temperature only.  
The diffusion coefficients for Congo Red and Sudan Black B however, could not 
be calculated accurately due to significant evaporation (> 20%). The calculated diffusion 
coefficient, DCongo Red RT for Congo Red at room temperature was determined to be 1.8 
mm
2/hr and 2.1 mm
2/hr for DCongo Red 37°C. (Since novel hydrogels are being used the  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A B  
Figure 7: Calibration curve of Piroxicam: A) Piroxicam in DPBS plus 0.5% by volume Tween 20, B) Piroxicam in 
PLGA-PEG-PLGA; 1,142-1,000-1,142 (2.7:1, DL-lactide/glycolide). All readings were done at; Emax = 276 nm. 
________________________________________________________________________ 
diffusion coefficient of Congo Red out of this medium is unknown, and as a result, no 
comparison can be made.) In addition to evaporation, the supernatant contained only 
DPBS, which may explain the initial 1.93% release of Sudan Black B, over the first 5 
hours followed by a plateau. (Data not shown). As previously mentioned, the addition of 
0.5% by volume of Tween 20 could have aided in gathering more data points for Sudan 
Black B, thus allowing the determination of the diffusion coefficient. Piroxicam was also 
continuously released from AT-21 immersed in DPBS + 0.5% Tween 20 at physiological 
temperature. (Figure 8A) The diffusion coefficient DPiroxicam was calculated to be 24.56 
mm
2/hr. The diffusion coefficient of Congo Red at physiological temperature is slower 
than that of carmustine, 5.148 mm
2/hr and paclitaxel, 3.24 mm
2/hr, while Piroxicam is 
much faster, making both dyes unsuitable for analogs. The rate of release of Piroxicam 
(Figure 8B) dropped exponentially over time and was approximated as follows [16]:  
                                                                                    (11)  
where tn is the time elapsed until collection of the n
th sample, and Mn is the mass of dye 
released into DPBS + 0.5% Tween 20 between fluid exchanges tn and tn-1. An interesting   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A  B   
Figure 8: Release Profile and Rate of Release of Piroxicam out of poly(ethylene glycol-co-L-lactide-co-glycolide) 
polymer PLGA-PEG-PLGA; 1,142-1,000-1,142 (2.7:1, DL-lactide/glycolide). A) Plot of cumulative mass % at Emax 
= 276 nm released over time. Insert is the linear region vs. square root of time. Dpiroxicam = 24.56 mm
2/hr B) Rate of 
release of Piroxicam over time. 
_______________________________________________________________________ 
phenomenon was observed; it appears that the hydrogel interacts with the dye, only 
allowing an initial release of dye, which can be considered to be in an unbound form with 
respect to the hydrogel. (Seen as the plateau on the release profiles.) One hundred percent 
cumulative release was not achieved for any of the release profiles. 21.5% of Congo Red 
was seen free to diffuse out of the matrix into the supernatant, while the remainder was 
bound. As previously mentioned, 1.93% of Sudan Black B was free to diffuse and 29.3% 
for Piroxicam. It can be assumed, then, that the difference is the percentage of the binding 
interactions between the polymer and dye. However, this inference can only be 
qualitative because there is no standard to quantitatively compare too.  
BRAIN PHANTOMS 
Two brain phantoms were injected with AT-19/Congo Red hydrogel solutions, 
and the percentage of dye remaining in the matrix after t = 3 and 7 days were found to 
exponentially decrease. (Figure 9a) A similar result was observed with AT-21/Piroxicam 
hydrogel solutions when samples were taken at t = 1,3 and 7 days. (Figure 9b) However,  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at t = 7 days the percentage remaining was 74.4%. (Data not shown). This problem arises 
because each time-point requires a separate brain phantom, therefore, release is not 
continuous from the same polymer over the entire experiment despite the solutions being 
nearly identical in each phantom. The result seen for t = 7 days may have been from a 
combination of binding interactions between the polymer matrix and the volume of the 
resection cavity decreasing. A decrease in the resection cavity volume results when the 
inflated ET tube is placed in a hot media causing the balloon to deflate. The shape of the 
curve indicates that the hydrogel is establishing a typical first-order controlled release 
mechanism and is consistent with a diffusion-controlled release mechanism. If these 
experiments were allowed to run until all of the dye was released from the matrix into the 
surrounding agarose, the release mechanism would likely have been faster than a purely 
diffusion-controlled mechanism, which would likely be the result of combined diffusion 
and polymer degradation mechanisms. [29] Since convection results in higher fluid 
velocities than diffusion, the presence of a minimal amount of convection could make a 
substantial difference. 
________________________________________________________________________ 
A B  
Figure 9: Time-lapse diffusion of Congo Red out of thermo-gelling hydrogel from resection cavity of brain 
phantom model. A) 33% of the resection cavity in the brain phantom model was filled with PLGA-PEG-PLGA 
hydrogel loaded with Congo Red and absorbance was read at 3 and 7 days post-injection. B) Repeated experiment 
instead with Piroxicam readings taken at 1 and 3 days post-injection. (At Day 7: 74.40% still remained in the cavity). 
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It was also observed that the hydrogel was not allowed to completely solidify in 
the resection cavity of the brain phantom. This may have been the result of increasing 
water content due to “sweating” when the polymer was loaded into the phantom and 
allowed to solidify in the resection cavity. 
TRANSPORT MODEL 
   Keeping all parameters consistent with our lab’s previous study, the transport 
model was run with different arrangements of hydrogel within the resection cavity. [32] 
________________________________________________________________________ 
A    B   C    
D      E     F  
 G   H      I  
Figure 10: Computer Simulation of Drug Release into Brain when filling the resection cavity: A) 30% 
carmustine-loaded hydrogel, B) 50% carmustine-loaded hydrogel, C) Corrected 50% carmustine-loaded hydrogel D) 
66% carmustine-loaded hydrogel, E) 30% paclitaxel-loaded hydrogel, F) 50% paclitaxel-loaded hydrogel, G) 66% 
paclitaxel-loaded hydrogel. H) 1.0 mm lining of paclitaxel-loaded hydrogel, I) 3.0 mm lining of paclitaxel-loaded 
hydrogel. Displayed concentrations have cut-off values to account for differences in minimum therapeutic 
concentrations of carmustine (0.0150 mol/m
3) and paclitaxel (8.90x10
-4 mol/m
3)  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The model hydrogel was loaded with either paclitaxel or carmustine and run for a 
simulated 30 days (the maximum time where predictable release can be expected due to 
the onset of polymer degradation). 
The surface concentration was kept constant at 2.34 mol/m
3 for comparative 
analysis; each simulation was repeated for carmustine and paclitaxel loaded in hydrogel 
and compared with the release from Gliadel
® wafers. The two-dimensional resection 
cavity is represented by a circle with a diameter of 2.0 cm corresponding with a spherical 
volume of 4.19 cm
3 in three dimensions.  
The cavity was filled with 30%, 50% or 60% with a thermo-gelling polymer 
matrix. (Figure 10a-f) Release of carmustine when the hydrogel filled 30% and 60% of 
the resection cavity showed no penetration into the surrounding tissue; and only a small 
amount of penetration into the resection cavity when the resection cavity was filled 30%. 
(Figure 10a, c) However, filling 50% of the cavity with carmustine-loaded hydrogel 
yielded significant penetration of the minimum therapeutic concentrations into the 
surrounding brain. (Figure 10b) Upon review, several of the boundary parameters in the 
model were incorrect, and when corrected, the model yielded similar results to filling the 
resection cavity 30% and 66%. (Figure 10i) Filling the resection cavity with any of the 
three percentages was less effective than Gliadel
® wafers at 36 hours post implantation, 
therefore, not an effective arrangement. (Figure 11a) Compared with paclitaxel-loaded 
hydrogels, increased penetration of drug was seen in all three arrangements (30%, 50%, 
and 60%), however, penetration of paclitaxel was limited to only about 4.0 – 5.0 mm. 
(Figure 10d-f) This is slightly better than release from the Gliadel
® wafers at 30 days post 
implantation. (Figure 11b)  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Further simulations were run with the thermo-gelling polymer matrix lining the 
resection cavity with a 1.0 mm or a 3.0 mm thickness. (Figure 10g and h) When lining 
the resection cavity with carmustine-loaded hydrogels, neither with 1.0 mm nor 3.0 mm 
layers, at the same surface concentration, showed any result. The surface concentration 
needed to be at least three orders of magnitude higher (a concentration that would 
certainly be above the maximum tolerated dose (MTD) for carmustine) to provide results. 
This most likely results from the concentration being smaller than the elimination 
constant of carmustine in the cavity, blood capillaries, and from enzymatic/non-
enzymatic reactions, all of which are incorporated into the transport model. Since the 
concentration is smaller than the elimination constant, carmustine is eliminated from the 
system at a rate that does not allow for penetration and therapeutic benefits.  
Lining with paclitaxel-loaded hydrogel at both thicknesses showed penetration 
into the surrounding brain, only at a distance of a few millimeters. (Figure 10g,h) 
________________________________________________________________________ 
A B  
Figure 11: Carmustine release from Gliadel
® wafers in transport model: Drug penetration profile of carmustine (a) 
36 hours post implantation and (b) 30 days post implantation. Displayed concentrations have cut-off values to account 
for differences in minimum therapeutic concentrations of carmustine (0.0150 mol/m
3)  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Employing a 1.0 mm layer of paclitaxel-loaded hydrogel around the resection cavity 
provided the greatest penetration to the resection cavity and surrounding brain 
parenchyma. This thickness could be obtained by coating the cavity with the gel or 
immobilizing it on a scaffold (e.g., Surgicel
TM). Lining the resection cavity proves to be 
the most optimal arrangement of the hydrogel within the resection cavity. Despite all 
paclitaxel loaded hydrogel configurations exhibiting approximately the same amount of 
penetration, lining the cavity would allow more drug to diffuse out rather than being 
trapped in the polymer matrix, a result of the surface area to volume ratio, exhibited when 
comparing Figure 10f and 10h. A 1.0 mm lining or slightly greater ( < 3.0 mm) would 
provide the best penetration, which is better then the standard Gliadel
® wafers.  
DISCUSSION 
  Discovering effective novel delivery mechanisms of anticancer agents to treat 
malignant gliomas is a challenging task. Currently, there exists a wide range of 
treatments for primary and relapsed/recurrent malignant gliomas. Local delivery of 
chemotherapeutic agents is a promising treatment modality. However, many factors 
prevent drug diffusion to the tumor in both local and systemic treatment, the greatest 
being the BBB.  
  The BBB is a combination of a basement membrane and an endothelial 
monolayer that allows only lipophilic molecules smaller than ~500 Da to pass through. 
[35] For drugs to penetrate the BBB, the drug must be lipophilic (e.g., paclitaxel or 
BCNU), targeted towards a membrane transporter, and/or the BBB needs to be 
osmotically disrupted (e.g., super-selective intra-arterial cerebral infusion after mannitol 
disruption) or its vasculature permeabilized. [35, 36] However, even when treatments  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eventually pass the BBB, their concentrations are usually too low to be effective. BCNU 
or the more lipophilic paclitaxel will readily traverse the BBB, but only a limited number 
of tumor cells will be killed while leaving normal cells alone, and it is not possible to 
conjugate targeting moieties while maintaining the necessary size for crossing. [35] As a 
result, local delivery methods are essential. 
  BCNU has been the standard of care for localized delivery, but despite being well 
tolerated from a toxicity perspective, it only produces moderate results in prolonging OS 
due to a sharp decrease in concentration as the distance from the implant site increases. 
[35] As a result, the flux of drug from the implant to the surrounding brain parenchyma is 
mostly a function of the concentration at the implant site. This limitation, in addition to 
the short half-life of BCNU, and high capillary permeability, leads to the search of new, 
more effective lipophilic drugs and methods such as the novel thermo-gelling hydrogels 
used in this study.  
The much more hydrophobic paclitaxel may be a more effective drug of choice 
because of the slower degradation rate and decreased capillary permeation in brain tissue. 
[16] Though the diffusivity of paclitaxel is similar to carmustine, it is subjected to much 
less elimination by transcapillary exchange mainly due to its larger molecular size. [33] It 
is also a known radio-sensitizer and could be combined with radiation therapy to increase 
the effective targeting and killing of cancerous cells, thus making it a good candidate for 
localized delivery. [32, 37]  
The employment of thermo-gelling polymers used in this study allows for a 
greater choice of therapeutic agents to be delivered for prolonged, sustained, continuous, 
and predictable concentrations and time periods. However, as shown filling the 30%,  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50% or 60% of the resection cavity with the hydrogel, which subsequently conforms to 
the shape of the cavity, is not optimal for delivering effective concentrations of 
hydrophobic drugs to the brain parenchyma. When the hydrogel takes this arrangement 
within the resection cavity, the volume to surface area ratio is dramatically decreased, 
therefore, inhibiting a majority of the drug from diffusing out. This poses a potential risk 
when the polymer matrix starts to degrade, allowing for a sudden uncontrolled burst of 
drug into the surrounding brain. A sudden burst can lead to an adverse effect if the 
concentration is at or above the maximum tolerated dose for that particular drug.  
This same phenomenon of reduced volume to surface area ratio is seen with the 
Gliadel
® wafers. After trauma, the immediate physiological immune response is for the 
brain to swell. When this occurs in the brain after surgery, the resection cavity decreases 
in volume and the wafers that once lined the cavity will become stacked and, as a result, 
dramatically decrease the volume to surface area ratio, subsequently trapping a majority 
of carmustine and decreasing the efficacy of release. This phenomenon may help to 
partially explain the observed release profile curves; the thickness of the hydrogel may 
act similarly to the stacked wafers and trap the majority of the dye in the polymer matrix. 
It is possible that a layer less than 3 mm would yield a higher cumulative release. 
Additionally, binding interactions between the polymer matrix and the dye/drug may also 
help to explain why significantly less than 100% cumulative mass release was observed.  
The synthesis of novel block co-polymers has led to the creation of a wide variety 
of stimuli-sensitive hydrogels, including thermo-sensitive, pH sensitive, and combined 
pH- and thermo-sensitive co-polymers. In addition, to various stimuli-sensitive 
hydrogels, the actual composition of hydrogels can also vary, such as poly(n-substituted  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acrylamide)-based, poly(vinyl ether)-based, poly(ethylene oxide)-b-poly(propylene 
oxide)-b-poly(ethylene oxide) triblock polymers, also known as (Pluronic ®) or 
Poloxamer ®, or PEG and PLGA di- and tri-block co-polymers. [38] Depending on the 
function wanted and the location of implantation, different compositions are required. 
One of the original tri-block co-polymers was the PEG-PLGA-PEG tri-block; however, 
despite showing significant efficacy and a decrease in systemic adverse effects in 
Sprague-Dawley (SD) rats, newer generations of PLGA-PEG-PLGA tri-blocks were 
created. [38] 
Choosing to synthesize novel thermo-gelling PLGA-PEG-PLGA hydrogels was 
fairly simple. Firstly, when treating in the brain, the pH does not and should not fluctuate; 
therefore, employing pH-sensitive hydrogels would not make sense (and could lead to 
adverse or even lethal effects if the pH of the brain were to fluctuate enough to activate 
the hydrogel sol-gel-sol phase transition). PLGA-PEG-PLGA tri-block co-polymers have 
already previously been shown to be efficacious in preliminary animal model studies, as 
well as clinical trials, and PLGA-PEG-PLGA polymers for therapy are already 
commercially available as ReGel
® and OncoGel
® (ReGel/paclitaxel). [23, 38]  
Also, the synthesis of PLGA-PEG-PLGA has proven to be simpler than that of 
PEG-PLGA-PEG. The coupling procedure used to synthesize PEG-PLGA-PEG, 
hexamethylene diisocyante (HMDI), can be avoided. Another key difference between the 
two that makes PLGA-PEG-PLGA more desirable for the local treatment of gliomas, is 
PLGA-PEG-PLGA exhibited a reversible sol-gel-sol transitions with increasing 
temperature, along with other differences described in He et al. [38]   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Brain phantoms are useful representations of the in vivo brain for testing 
diffusivity, novel treatments such as our thermo-gelling polymeric carriers, convection 
enhanced delivery (CED), and many more. The macroscopic characteristics of 0.6% 
agarose gel replicate that of the brain for surgical insertion of probes and are ideal for 
testing infusion studies. [31] However, major properties of the in vivo brain are ignored, 
such as differentiating between grey and white matter. The model is largely homogenous 
and isotropic, while brain tissue is quite inhomogeneous and highly anisotropic, 
especially in the white matter. Therefore, the flow pattern of the model would likely not 
replicate the natural complex flow pattern of the in vivo brain. [31] Secondly, the model 
is inert and unperfused, while brain tissue is quite perfused, making this model not useful 
for evaluating the uptake or clearance of agents in the brain. [31]  
Many of the same properties are also ignored in our computational model. In 
order to provide a more realistic simulation in both the brain phantom and the computer 
model, these properties need to be considered. Computational modeling of drug transport 
to the brain showed only slight penetration, on the order of millimeters, into the brain. As 
previously mentioned, GBM tumors usually recur on the order of centimeters away from 
the initial resection site, therefore, drug penetration must reach these outlying malignant 
cells that persist in the tissue after resection. [16-18] Newer drugs that are angiogenesis 
inhibitors or immunomodulators, [15] such as bevacizumab, erlotinib, or temozolamide 
may provide better penetration; however, this still must be explored. Concurrent or 
combined treatment with other modalities such as stereotactic radiosurgery or cytokine 
immunotherapy [15] may also prove beneficial. It has been shown that concurrent  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chemotherapy and radiosurgery have been able to prolong progression free survival 
(PFS) and OS slightly. [27, 36, 39, 40] 
FUTURE STUDIES 
Characterization and finding suitable dye analogs to paclitaxel or carmustine are 
needed. These analogs must have similar critical physical properties such as molecular 
weight and diffusivity. The release profile of Congo Red should be repeated, with 
minimizing evaporation following the procedure used for determining the Piroxicam 
release profile, considering the similarity to both paclitaxel and carmustine. In addition, 
the binding interaction must be characterized, and once this is accomplished, synthesize 
new tri-block thermo-gelling hydrogels that have protective groups to decrease the 
binding interactions. This may help achieve a greater sustained and controlled release of 
drug before the combined degradation/diffusion process begins. Additionally, the 
arrangement of the hydrogels still needs to be optimized to find penetration results 
comparable or better than the Gliadel
® wafers. It is possible that completely new 
hydrogels need to be created to solve both of these problems. Furthermore, more realistic 
computer and brain phantom models should be constructed to account for the anisotropic 
and inhomogeneous properties of the in vivo brain as well as to differentiate between grey 
and white matter. 
CONCLUSION 
  Thermo-gelling hydrogels are potentially novel alternative drug delivery systems 
for the localized treatment of GBM. In this study, the hydrogels used showed a 
controlled, but not sustained first-order release mechanism. Release was seen only to 
cumulative mass percentage of approximately 30%, which would provide few therapeutic  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benefits for the patient. Release is inhibited by strong binding interactions between the 
dye and polymer matrix, therefore, further study is necessary to determine if this binding 
interaction can be avoided so higher release can be achieved. Fluorescein, Congo Red, 
Sudan Black B and Piroxicam are not suitable analogs for in vitro experiments of 
paclitaxel or carmustine. The diffusion coefficient of Piroxicam (24.6 mm
2/hr) was much 
faster than that of carmustine and paclitaxel, 5.148 mm
2/hr and 3.24 mm
2/hr respectively, 
while the diffusion coefficient of Congo Red at physiological temperature (2.1 mm
2/hr) 
was similar despite substantial evaporation. Computational modeling showed that lining 
the resection cavity with a 1.0 mm thick polymer matrix may provide the best therapeutic 
penetration; however, further study is required to optimize the therapeutic concentrations 
penetrating into surrounding brain parenchyma. 
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APPENDIX A – Library of Hydrogels 
Sample  Code  Date of synthesis  Date of 
GPC 
Mn  Mw  PDI  Mn by 
NMR 
PCL-PEG-PCL 
2,000-2,000-2,000 
AT1 
03-05-10 
 
05-04-10 
     
 
PCL-PEG-PCL 
1,000-1,000-1,000 
AT2 
03-16-10 
 
05-04-10  6371  7720  1.21 
 
PCL-PEG-PCL 
2,000-2,000-2,000  AT3 
03-18-10 
 
05-04-10  6263  8152  1.30 
 
PCL-PEG-PCL 
1,000-1,000-1,000  AT4 
04-20-10 
 
05-06-10 
4058 
4822  1.18 
 
PCL-PEG-PCL 
1,000-1,000-1,000 
AT5 
04-27-10 
 
05-06-10  6303  8003  1.27 
 
PCL-PEG-PCL 
750-1,000-750  AT6 
04-27-10 
 
05-06-10  3457  4284  1.23 
 
PLGA-PEG-PLGA 
2,000-2,000-2,000 
AT7 
03-22-10 
 
05-07-10  6291  8254  1.31 
 
PLGA-PCL-PEG-PCL-PLGA 
1,000-1,000-2,000-1,000-1,000 
AT8  03-21-10 
04-01-10 
05-07-10  7834  8897  1.14 
 
PLGA-PCL-PEG-PCL-PLGA 
500-500-1,000-500-500 
AT9  03-21-10 
04-01-10 
05-07-10  3623  4038  1.11 
 
PCL-PLGA-PEG-PLGA-PCL 
1,000-1,000-2,000-1,000-1,000  AT10  03-22-10 
04-10-10  05-07-10  7420  9279  1.25 
 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(1:1, L-lactide/glycolide) 
AT11  04-10-10  05-07-10  3203  3993  1.25  2978 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(3:1, L-lactide/glycolide) 
AT12 
05-22-10 
 
06-08-10  2149  2557  1.19 
 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(3:1, L-lactide/glycolide) 
AT13 
05-22-10 
 
06-08-10  2220  2617  1.18 
 
PCLA-PEG-PCLA 
1,000-1,000-1,000  AT14  05-27-10  06-08-10  2937  3456  1.18 
 
PCLA-PEG-PCLA 
1,000-1,000-1,000 
AT15  05-29-10  06-08-10  2842  3337  1.17 
 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(3:1, DL-lactide/glycolide) 
AT16   
05-20-10 
06-08-10  2026  2383  1.18 
 
PLGA-PEG-PLGA 
1,500-1,000-1,500 
(3:1, DL-lactide/glycolide) 
AT17 
06-11-10 
 
06-14-10  4815  6147  1.28 
 
PCL-PEG-PCL 
7,000-1,000-7,000  AT18   
06-11-10 
06-14-10  3190  4051  1.29 
 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(3:1, DL-lactide/glycolide) 
AT19   
06-16-10  06-17-10  3280  3690  1.13  2948 
PLGA-PEG-PLGA 
1,200-1,000-1,200 
(3:1, DL-lactide/glycolide) 
AT20  06-30-10  07-02-10  2608  2943  1.13 
 
PLGA-PEG-PLGA 
1,250-1,000-1,250 
(3:1, DL-lactide/glycolide) 
AT21  07-28-10  09-08-10  3075  3688  1.20  3260 
PLGA-PEG-PLGA 
1,250-1,000-1,250 
(1:1, L-lactide/glycolide) 
AT22  07-28-10  08-02-10  2714  3326  1.23 
 
PLGA-PEG-PLGA 
1,250-1,000-1,250 
(3:1, DL-lactide/glycolide) 
AT23  08-04-10  09-08-10  2531  2760  1.09  2760 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(1:1, L-lactide/glycolide) 
AT24  08-04-10  09-08-10  3366  4100  1.22  3730 
PLGA-PEG-PLGA 
1,000-1,000-1,000 
(1:1, L-lactide/glycolide) 
AT25  08-06-10  09-08-10  2833  3376  1.19  3000  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APPENDIX B – Release Curves of Congo Red  
A    
B  
A) The release profile of Congo Red at room temperature. B) The release profile at 37°C.  
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